GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiomX Inc (AMEX:PHGE) » Definitions » Intangible Assets

BiomX (PHGE) Intangible Assets : $15.79 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BiomX Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. BiomX's intangible assets for the quarter that ended in Mar. 2024 was $15.79 Mil.


BiomX Intangible Assets Historical Data

The historical data trend for BiomX's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiomX Intangible Assets Chart

BiomX Annual Data
Trend Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial - 3.04 1.52 - -

BiomX Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 15.79

BiomX Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


BiomX  (AMEX:PHGE) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


BiomX Intangible Assets Related Terms

Thank you for viewing the detailed overview of BiomX's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


BiomX (PHGE) Business Description

Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.
Executives
Assaf Oron officer: Chief Business Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Michael E. Dambach director 22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003
Jason M. Marks director C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Carl L Gordon 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Biofund Gp Limited Partnership director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Chidozie Ugwumba 10 percent owner 158 FILMORE STREET, DENVER CO 80206
Thomas Layton Walton 10 percent owner P.O. BOX 1860, BENTONVILLE AR 72712
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Lynne Marie Sullivan director C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Marina Wolfson officer: Principal Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Jonathan Eitan Solomon director, officer: Chief Executive Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Russell Greig director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004